Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Breast Cancer, Postoperative Pain, Infla...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Sleep quality is a key physiological factor influencing immune function, inflammatory response, and pain perception. This prospective observational study aims to evaluate whether preoperative sleep quality predicts postoperative inflammation, pain severity, and analgesic consumption in patients undergoing elective breast cancer surgery. Preoperative sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). Systemic inflammatory response will be evaluated using the Systemic Immune-Inflammation Index (SII), calculated from routine hematological parameters. Postoperative pain will be assessed using the Visual Analog Scale (VAS), and analgesic consumption will be recorded within the first 24 hours. The study aims to determine whether poor sleep quality is associated with increased inflammatory response, higher pain scores, and greater analgesic requirement.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Preoperative Sleep Quality Assessment (PSQI) — Preoperative sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated self-reported questionnaire evaluating sleep quality over the previous month. Based on PSQI scores, patients will be categorized into two cohorts: good sleep quality (PSQI ≤ 5) and poor sleep quality (PSQI \> 5). No intervention or modification to standard clinical care will be applied. All perioperative management will be conducted according to routine institutional protocols. This study is purely observational, and the PSQI assessment is used solely for grouping and analytical purposes.

Primary Outcomes

  • Postoperative Systemic Inflammatory Response (SII) (At 24 hours postoperatively (± 6 hours))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04-01
Completion: 2026-07-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
Contact Information
Study Contact:
Mustafa Kemal Şahin
+905075800976
mksahin@msn.com
Mustafa Kemal SAHIN, Dr
+905075800976
mksahin@msn.com
Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Rea
Interventions
  • Other: Preoperative Sleep Quality Assessment (PSQI) — Preoperative sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), a validated self-reported questionnaire evaluating sleep quality over the previous month. Based on PSQI scores, patients will be categorized into two cohorts: good sleep quality (PSQI ≤ 5) and poor sleep quality (PSQI \> 5). No intervention or modification to standard clinical care will be applied. All perioperative management will be conducted according to routine institutional protocols. This study is purely observational, and the PSQI assessment is used solely for grouping and analytical purposes.
Study Locations (1 sites)
Dr. Abdurrahman Yurtaslan Ankara Oncology Education and Research Hospital Clinic of Anesthesiology and Rea, Ankara, Yenimahalle 06200 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Female patients aged 18 to 70 years * Scheduled for elective breast cancer surgery * American Society of Anesthesiologists (ASA) physical status I to III * Able to understand and complete the Pittsburgh Sleep Quality Index (PSQI) * Willing to participate in the study * Provided written informed consent Exclusion Criteria: * Active infection * History of chronic inflammatory disease or autoimmune disease * Use of steroids or immunosuppressive drugs within the past 6 months * Known diagnosis of obstructive sleep apnea syndrome * Severe cognitive impairment preventing completion of the questionnaire * Planned emergency surgery * Refusal to participate or failure to provide informed consent
Conditions Alzheimer Dementia (AD), Diabete Type 2
Phase Not Applicable
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Alzheimer's disease is the most common cause of dementia and affects a growing number of older adults. Although harmful proteins build up in the brain, we still do not fully understand why some brain regions are affected earlier or more severely than others. Many people with Alzheimer's disease also have problems with blood flow and sugar handling in the brain, and these changes may play an important role in disease development. People with type 2 diabetes are at especially high risk of developing Alzheimer's disease and often experience a more severe disease course. This pilot study aims to improve our understanding of how brain blood flow and sugar use are altered in Alzheimer's disease, and whether these changes differ in people with and without type 2 diabetes. We will study three groups: people with Alzheimer's disease without diabetes, people with Alzheimer's disease and type 2 diabetes, and healthy older individuals. By comparing these groups, we aim to identify early brain changes that may contribute to cognitive decline. Participants will undergo advanced brain imaging using positron emission tomography (PET) scans. One scan uses a radioactive sugar tracer to measure how the brain takes up and uses glucose. Importantly, a new non-invasive method will also allow us to estimate how efficiently glucose is transported from the blood into the brain. This is a key process that may be impaired in Alzheimer's disease, but has previously required invasive procedures. The new approach avoids arterial cannulation, making the study safer and more comfortable for participants. A second PET scan will assess brain blood flow and blood vessel function, including how well the vessels can respond to increased demand. Participants will also complete cognitive tests to assess memory and thinking abilities. Ultimately, this research may contribute to earlier diagnosis, better monitoring of disease progression, and development of new treatment strategies for Alzheimer's disease.

Design

Study type: Observational Observational model: Case Control Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: [18F]FDG PET — Regional glucose metabolism as well as glucose transport will be assessed.
  • Diagnostic Test: [11C]PIB — Early perfusion PET after acetazolamide infusion as well as late amyloid load will be assessed.

Primary Outcomes

  • Glucose transport (at inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03
Completion: 2026-12
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: true
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Rigshospitalet, Denmark
Collaborators: Copenhagen University Hospital at Herlev
Contact Information
Study Contact:
Lisbeth Marner, MD, DMSc, PhD
+4538682041
Lisbeth.marner@regionh.dk
Lisbeth Marner, MD, DMSc, PhD
+4538682041
Lisbeth.marner@regionh.dk
Copenhagen University Hospital Herlev
Lisbeth Marner, MD, DMSc, PhD
Copenhagen University Hospital Herlev
Interventions
  • Diagnostic Test: [18F]FDG PET — Regional glucose metabolism as well as glucose transport will be assessed.
  • Diagnostic Test: [11C]PIB — Early perfusion PET after acetazolamide infusion as well as late amyloid load will be assessed.
Study Locations (1 sites)
Copenhagen University Hospital Herlev, Herlev, 2730 Denmark
Eligibility Criteria
Inclusion Criteria: * suspected Alzheimer's disease * type 2 diabetes (group A) * able and willing to comply with study protocoil´´l Exclusion Criteria: * type 2 diabetes (group B and C) * significant brain disease apart from dementia (group A and B) * significant vascular or neurological disease (group C) * active cancer treatment * history of alcohol or drug abuse * severe claustrophobia * pregnancy or breastfeeding
Conditions Asthma COPD
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Unicentric retrospective study designed to analyses the performance of various machine learning approaches to predict patterns of chronic respiratory diseases such as asthma, based mainly on clinical information and respiratory spirometry/oscillometry.

Design

Study type: Observational Observational model: Other Time perspective: Retrospective

Interventions / Regimen

  • Other: 1 — Compare oscillometry results with spirometryClick to apply

Primary Outcomes

  • Oscillometric breathing pattern (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-15
Completion: 2026-09-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Principal Investigators:
  • Astrid Crespo-Lessmann, PhD (PRINCIPAL_INVESTIGATOR) - Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact Information
Study Contact:
Astrid Crespo, PhD
+34-935565972
acrespo@santpau.cat
Astrid Crespo-Lessmann, PhD
+34-935565972
acrespo@santpau.cat
Astrid Crespo Lessmann, MD
+34-935565972
acrespo@santpau.cat
Hospital de la Santa Creu i Sant Pau
Interventions
  • Other: 1 — Compare oscillometry results with spirometryClick to apply
Study Locations (1 sites)
Hospital de la Santa Creu i Sant Pau, Barcelona, 08041 Spain
Eligibility Criteria
Inclusion Criteria: * 18 - 90 years * Spirometry available * Confirmed clinical diagnosis of COPD, asthma, interstitial lung disease according to national or international guidelines Exclusion Criteria: * Acute respiratory infection
Conditions Elevated Pulmonary Artery Pressure
Phase NA
Enrollment 12
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if synchronous telerehabilitation is effective in patients with elevated pulmonary artery pressure identified by echocardiography (systolic pulmonary artery pressure ≥50 mmHg). It will also evaluate the effects of telerehabilitation on exercise capacity, dyspnea, fatigue, functional status, and quality of life. The main questions it aims to answer are: Does synchronous telerehabilitation improve exercise and functional capacity in these patients? Does synchronous telerehabilitation improve dyspnea, fatigue, psychological status, and quality of life? Researchers will compare synchronous telerehabilitation with breathing and posture exercises to see if telerehabilitation provides greater clinical and functional benefit. Participants will: Be randomly assigned to one of 2 groups Follow an 8-week program, 3 times per week, for 30 minutes per session Perform aerobic, endurance, and strengthening exercises by synchronous telerehabilitation, or breathing and posture exercises in the control group Complete assessments before and after treatment

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Synchronous Telerehabilitation — A supervised synchronous telerehabilitation program delivered via videoconferencing, including aerobic, endurance, and strengthening exercises for 8 weeks, 3 times per week, 30 minutes per session. The program will be individualized based on participant tolerance and clinical findings, with monitoring of symptoms and physiologic responses during exercise.
  • Behavioral: Breathing and Posture Exercises — A control intervention consisting of breathing exercises, positions to relieve breathing discomfort, breathing control techniques, energy conservation strategies, and posture exercises, performed for 8 weeks, together with routine care and weekly motivational follow-up.

Primary Outcomes

  • Exercise Capacity (Baseline and at 8 weeks)
  • Dyspnea severity measured by the Modified Borg Dyspnea Scale (Baseline and at 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04
Completion: 2026-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Marmara University
Collaborators: Tokat Gaziosmanpasa University
Principal Investigators:
  • Aysel Yıldız Özer, PhD (STUDY_DIRECTOR) - Marmara University
Contact Information
Study Contact:
Mehmet Armağan Physiotherapist, Msc
00903562521616
mehmetarm@gmail.com
Mehmet Armağan
00903562521616
mehmetarm@gmail.com
Tokat Gaziosmanpaşa University
Interventions
  • Behavioral: Synchronous Telerehabilitation — A supervised synchronous telerehabilitation program delivered via videoconferencing, including aerobic, endurance, and strengthening exercises for 8 weeks, 3 times per week, 30 minutes per session. The program will be individualized based on participant tolerance and clinical findings, with monitoring of symptoms and physiologic responses during exercise.
  • Behavioral: Breathing and Posture Exercises — A control intervention consisting of breathing exercises, positions to relieve breathing discomfort, breathing control techniques, energy conservation strategies, and posture exercises, performed for 8 weeks, together with routine care and weekly motivational follow-up.
Study Locations (1 sites)
Tokat Gaziosmanpaşa University, Tokat Province, Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 65 years * Elevated pulmonary artery pressure identified by echocardiography, defined as systolic pulmonary artery pressure (sPAP) of 50 mmHg or higher * Clinically stable and receiving medical treatment under cardiology follow-up World Health Organization functional class I or II * New York Heart Association (NYHA) functional class I or II * Living with a caregiver, family member, or another person who can provide assistance if needed * Access to the internet and adequate visual, cognitive, and functional ability to participate in videoconference-based sessions * Willing to participate and able to provide informed consent Exclusion Criteria: * Requirement for oxygen therapy * Musculoskeletal problems limiting participation in exercise * Ongoing treatment for psychiatric or psychological disorders * Cognitive impairment based on Mini-Mental State Examination findings * Severe chronic obstructive pulmonary disease (COPD) * Other significant cardiac disease that may interfere with participation or assessment
Conditions Stage 1 Hypertension
Phase Not Applicable
Enrollment 12000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a prospective, multicenter, observational study to evaluate the effectiveness of Olmetec® or Olmetec Plus® on nocturnal blood pressure control in Korean patients with stage 1 hypertension. Patients receiving Olmetec-based therapy in routine clinical practice will be followed to assess changes in ambulatory blood pressure, including nocturnal blood pressure and blood pressure variability.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in mean 24-hour systolic blood pressure (Baseline to 12 weeks (up to 20 weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-17
Completion: 2027-01-31
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 12000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Daewoong Pharmaceutical Co. LTD.
Contact Information
Study Contact:
Yun Jeong Kong
82-10-3206-5162
yjkong246@daewoong.co.kr
Yun Jeong Kong
82-10-3206-5162
yjkong246@daewoong.co.kr
Multiple centers in Republic of Korea
Interventions
N/A
Study Locations (1 sites)
Multiple centers in Republic of Korea, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Adults aged ≥19 years * Patients diagnosed with stage 1 hypertension according to clinical guidelines * Patients who are newly prescribed Olmetec® or Olmetec Plus® in routine -clinical practice * Patients who are able to undergo ambulatory blood pressure monitoring (ABPM) * Patients who voluntarily agree to participate and provide written informed consent Exclusion Criteria: * Patients with secondary hypertension * Patients with severe hypertension requiring immediate pharmacological i-ntervention * Patients with known hypersensitivity to olmesartan medoxomil, hydrochlorothiazide, or any component of the study drugs * Patients who are pregnant, planning to become pregnant, or breastfeeding * Patients with severe renal impairment or severe hepatic impairment * Patients who are unable to comply with study procedures, including ABPM * Patients who are deemed inappropriate for participation by the investigator
Conditions Metastatic Breast Cancer
Phase PHASE1
Enrollment 170
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to find out the maximum tolerated dose (MTD) and/or recommended dose(s) for expansion (RDEs) of JNJ-101684362 (HLD-0117), to evaluate the safety of JNJ-101684362 (HLD-0117) , and how well the participants can tolerate it in Part 1 (dose escalation) of the study.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: JNJ-101684362 (HLD-0117) — A treatment cycle consists of 28 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)

Primary Outcomes

  • Dose Limiting Toxicities (DLTs) (28 days)
  • AEs, ECGs, Labs and Clinical Changes (28 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-04-09
Completion: 2029-10-10
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 170 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Janssen Research & Development, LLC
Principal Investigators:
  • Janssen Research & Development, LLC Clinical Trial (STUDY_DIRECTOR) - Janssen Research & Development, LLC
Contact Information
Study Contact:
Study Contact
844-434-4210
Participate-In-This-Study1@its.jnj.com
Interventions
  • Drug: JNJ-101684362 (HLD-0117) — A treatment cycle consists of 28 days. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Study Locations (6 sites)
Yale University School Of Medicine, New Haven, Connecticut 06510 United States
Florida Cancer Specialists, Sarasota, Florida 34236 United States
Massachusetts General Hospital, Boston, Massachusetts 02114 United States
SCRI Oncology Partners, Nashville, Tennessee 37203 United States
South Texas Accelerated Research Therapeutics, LLC (START), San Antonio, Texas 78229 United States
Next Virginia, Fairfax, Virginia 22031 United States
Eligibility Criteria
Inclusion Criteria: * Female (assigned at birth), greater than or equal to (\>=) 18 years old, and able to provide informed consent * Histologically confirmed metastatic or locally advanced breast cancer * Postmenopausal status defined by surgical or natural menopause, or ovarian suppression with a GnRH agonist * Prior therapy including 1. Must have received at least one endocrine therapy in the metastatic setting. 2. Must have received at least one cyclin-dependent kinase (CDK) 4/6i, either in the adjuvant and/or metastatic setting. 3. For Part 1 and Part 2 Cohorts 2A, 2B, 2C, and 2D: Participants may have received up to two prior distinct cytotoxic regimens (for example, taxanes, antibody-drug conjugates (ADCs), etc.) in the metastatic setting, unless discussed and approved by the medical monitor. 4. For Part 2 Cohort 2E: Participants must have received more than two prior distinct cytotoxic regimens (for example, taxanes, ADCs, etc.) in the metastatic setting. * Radiologic disease progression on the most recent therapy * Patients must have disease evaluable per response evaluation criteria in solid tumors (RECIST) v1.1 1. For Part 1 and Part 2B, 2C, and 2E: Participants may have either evaluable or measurable disease per RECIST v1.1. 2. For Part 2 Cohort 2A: Participants should have measurable soft tissue disease per RECIST v1.1. 3. For Part 2 Cohort 2D: Participants should have evaluable but not measurable disease. * Willingness to provide baseline and on-treatment tumor biopsies, unless not feasible or medically appropriate * For Part 1 and Part 2 (all cohorts): 1. Participants must have documented \>=10% ER staining and human epidermal growth factor receptor 2 (HER2) negative (per american society of clinical oncology \[ASCO\] college of american pathologists \[CAP\] guidelines) on the most recent tumor biopsy sample obtained. 2. For Part 2 Cohort 2B: Participants must have recent estrogen receptor 1 gene (ESR1) wild type from tumor or circulating tumor deoxy ribonucleic acid (ctDNA) testing performed after the most recent endocrine therapy prior to enrollment. 3. For Part 2 Cohort 2C: Participants must have ESR1 mutation detected from tumor or ctDNA testing performed prior to enrollment. * Eastern cooperative oncology group (ECOG) performance status 0-1 and life expectancy of at least 3 months * Adequate organ function Recovery from prior therapy-related toxicities to Grade \<=1 (except alopecia; neuropathy and endocrinopathies \<=Grade 2) * Ability to swallow oral medication and comply with study procedures * Stable dose (\>=30 days) of bisphosphonates or denosumab, if applicable Exclusion Criteria: * Participants with Inflammatory breast cancer or leptomeningeal disease or brain metastases, with the exception of patients with definitively treated brain metastases that are clinically stable and asymptomatic for \>2 weeks and who are off or receiving low-dose corticosteroid treatment (\<=10 mg prednisone or equivalent) for at least 2 weeks prior to start of study treatment. * Recent major bleeding or uncontrolled bleeding disorder * Ongoing corticosteroid use \>10 mg/day (prednisone equivalent) * Recent anticancer or investigational therapy within 14 days (28 days for fulvestrant) * Untreated or unstable spinal cord compression * Significant cardiovascular disease within 6 months or ongoing uncontrolled cardiac conditions * Active or uncontrolled infection (controlled HIV or treated hepatitis C allowed) * Uncontrolled renal, pancreatic, or liver disease (excluding stable conditions such as Gilbert's syndrome or liver metastases) * Another malignancy requiring treatment within 2 years (except low-risk, curatively treated cancers) * Major surgery within 28 days * Any condition that may interfere with safety or study compliance * Pregnancy or breastfeeding
Conditions Hypertension, Hypertension (HTN)
Phase NA
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn about the acute effects of beetroot extract in older women with high blood pressure. The main questions it aims to answer are: Does beetroot extract affect blood pressure during exercise? Does it change oxygen levels in the muscles? Participants will take a beetroot supplement and perform an aerobic exercise session to check how their bodies respond.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Dietary Supplement: Beetroot Extract (Nitrate-rich) — Participants will ingest 2 capsules of a standardized beetroot extract (Berkeley Life Nitric Oxide Foundation). Each dose provides approximately 314 mg of dietary nitrate.
  • Dietary Supplement: Placebo — Capsules identical in appearance, color, and size to the experimental supplement, but containing an inert substance (starch). This intervention is used to maintain the double-blind design of the study.
  • Behavioral: Exercise — Participants will perform a single aerobic exercise session on a treadmill. The protocol consists of a 7-minute warm-up followed by 30 minutes of continuous exercise at an intensity corresponding to 60-80% of maximum heart rate (HRmax), estimated using Tanaka's formula (208 - 0.7 \* age). Rate of Perceived Exertion (RPE) will be monitored periodically using the Borg scale (6-20).
  • Other: Rest (Control Condition) — Participants will remain seated for 30 minutes (matching the exercise session duration). During this time, a researcher will administer a Food Frequency Questionnaire (FFQ) in an interview format. This activity serves to assess dietary habits and simulates a routine, low-exertion daily activity (similar to a conversation), acting as a time-matched control for the exercise session.

Primary Outcomes

  • Systolic and Diastolic Blood Pressure (Baseline (Rest), during intervention (at 10 and 20 minutes), immediately post-intervention (at 30 minutes), and 10 minutes post-intervention recovery.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-10-08
Completion: 2026-07
Eligibility
Age: 60 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: São Paulo State University
Contact Information
Study Contact:
Anderson S Zago, Professor
+55 14 98199-9293
anderson.zago@unesp.br
Lucas K Carvalho, Master's student
+55 14 99799-2971
lk.carvalho@unesp.br
Anderson S Zago, Professor
anderson.zago@unesp.br
anderson.zago@unesp.br
São Paulo State University (UNESP)
Interventions
  • Dietary Supplement: Beetroot Extract (Nitrate-rich) — Participants will ingest 2 capsules of a standardized beetroot extract (Berkeley Life Nitric Oxide Foundation). Each dose provides approximately 314 mg of dietary nitrate.
  • Dietary Supplement: Placebo — Capsules identical in appearance, color, and size to the experimental supplement, but containing an inert substance (starch). This intervention is used to maintain the double-blind design of the study.
  • Behavioral: Exercise — Participants will perform a single aerobic exercise session on a treadmill. The protocol consists of a 7-minute warm-up followed by 30 minutes of continuous exercise at an intensity corresponding to 60-80% of maximum heart rate (HRmax), estimated using Tanaka's formula (208 - 0.7 \* age). Rate of Perceived Exertion (RPE) will be monitored periodically using the Borg scale (6-20).
  • Other: Rest (Control Condition) — Participants will remain seated for 30 minutes (matching the exercise session duration). During this time, a researcher will administer a Food Frequency Questionnaire (FFQ) in an interview format. This activity serves to assess dietary habits and simulates a routine, low-exertion daily activity (similar to a conversation), acting as a time-matched control for the exercise session.
Study Locations (1 sites)
São Paulo State University (UNESP), Bauru, São Paulo 17011-041 Brazil
Eligibility Criteria
Inclusion Criteria: * Female sex: Older women aged between 60 and 70 years. * Physical capability: Absence of health conditions that could compromise performance in the required physical exercise tests. Exclusion Criteria: * Smoking: Current smokers. * Alcohol use: History of alcohol abuse or excessive alcohol consumption. * Cardiovascular Disease: Diagnosis of cardiovascular diseases (other than the primary condition of hypertension).
Conditions Vascular Stiffness, Hypertension (HTN), ...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Low energy availability (LEA) occurs when the body does not get enough calories to support both daily life and exercise. This can happen when athletes train hard but do not eat enough to match their energy needs. In both 2012 and 2023, the International Olympic Committee on Sports Nutrition recognized LEA as an important factor that can increase the risk of cardiometabolic disease (CMD), which includes conditions like high blood pressure, diabetes, and heart disease. LEA can affect many systems in the body. It may disrupt hormones (such as menstrual cycles), cause changes in blood sugar and cholesterol levels, weaken bones, impair digestion, and negatively impact mental health. Over time, these changes may be linked to chronic inflammation, which plays a key role in the development of disease. Maintaining proper energy balance can be especially challenging for athletes because they often train at levels well above general health recommendations. As a result, even highly fit athletes may unintentionally remain in a calorie deficit. Our recent pilot research found a significant relationship between LEA and high blood pressure in Black Division I collegiate athletes. This is important because this group has historically been understudied and may face a higher risk of serious heart-related events, including sudden cardiac death. Despite assumptions that collegiate athletes are uniformly healthy, there is a need to better understand hidden health risks in this population. Our research aims to improve how we identify and monitor early signs of cardiometabolic disease by examining markers such as inflammation, blood sugar, and cholesterol levels. These insights will help healthcare providers, athletes, and families make more informed decisions about nutrition, training, and long-term health. Ultimately, this work seeks to develop practical, evidence-based strategies to protect athlete health and reduce the risk of serious cardiovascular outcomes.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Pulse wave velocity (PWV) (Enrollment to the second time point will not exceed 26 weeks. Testing once within the competitive season and once outside the competitive season (off season).)
  • Energy availability (Enrollment to the second time point will not exceed 26 weeks. Testing once within the competitive season and once outside the competitive season (off season).)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-06
Completion: 2028-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: North Carolina Agriculture & Technical State University
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Contact Information
Study Contact:
Troy M Purdom, PhD
13362853552
tpurdom@ncat.edu
Catherine Bush, PhD
3363347712
cmbush@ncat.edu
Troy M Purdom, PhD
3362853552
tpurdom@ncat.edu
North Carolina Agricultural & Technical State University
Interventions
N/A
Study Locations (1 sites)
North Carolina Agricultural & Technical State University, Greensboro, North Carolina 27411 United States
Eligibility Criteria
Inclusion Criteria: Age: 18-25yrs Sex: Male and Female Training Status/Experience: HBCU Division I collegiate athletes with \>3yrs of previous competitive experience Exclusion Criteria: * Persons who self-report any known disease, or unknown issue precluding collegiate competitive participation: Excluded * Those who have any orthopedic injuries, concussions, or conditions which would preclude safe testing: Excluded * Individuals who are not yet adults \<18yrs (e.g.: infants, children, teenagers): Excluded * Persons who have a pacemaker: Excluded * Persons who are pregnant: Excluded
Conditions Breast Cancer
Phase Not Applicable
Enrollment 600
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study adopts a multicenter, natural selection, observational design, and plans to enroll patients with HER-2 positive advanced or metastatic breast cancer treated at approximately 20 research centers nationwide. Patients with de novo stage IV disease or those with recurrent metastatic breast cancer who have not previously received trastuzumab, as well as patients with brain metastases, will be included for separate stratified efficacy analysis and will not be included in the overall analysis. The study plans to enroll effective data from 600 HER-2 positive advanced or metastatic breast cancer patients, who will be naturally allocated in a 1:1 ratio to either Group A (switching from HP + chemotherapy to HPy + chemotherapy) or Group B (switching from HPy + chemotherapy to HP + chemotherapy), with each group comprising approximately 300 patients. If first-line treatment fails, patients will switch to the alternative regimen in second-line treatment. All patients will continue treatment until disease progression, intolerable toxicity, or other reasons lead to discontinuation, with the number of treatment cycles recorded. The study is divided into three phases: screening/baseline period, treatment period (treatment period 1 + treatment period 2), and survival follow-up period. If patients develop intolerance to taxanes during treatment, clinicians may select alternative chemotherapy regimens such as vinorelbine, capecitabine, or eribulin based on clinical judgment. During the treatment period, patients will be followed up every two cycles, during which clinical data will be collected, including disease status assessments, laboratory tests, study drug usage, concomitant medications, and adverse events. After chemotherapy completion or treatment discontinuation, subsequent maintenance therapy, such as continued dual-targeted maintenance, may be administered by clinicians based on clinical needs until disease progression or intolerable toxicity occurs. Survival follow-up will be conducted every three months (for up to three years), with patient survival status recorded.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Drug: Antitumor treatment plan — This research project included valid data from 600 patients with HER-2 positive advanced or metastatic breast cancer. They were randomly divided into Group A (transition from HP + chemotherapy to HPy + chemotherapy) or Group B (transition from HPy + chemotherapy to HP + chemotherapy) in a 1:1 ratio. Each group had approximately 300 patients. If the patients failed in their first-line treatment, they would switch to another treatment regimen in the second-line treatment. All patients were stopped from treatment when their condition progressed, toxicity became intolerable, or for other reasons. The treatment cycles were recorded.

Primary Outcomes

  • PFS by Investigator assessment per RECIST 1.1 (60 mouths)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-01
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhejiang Cancer Hospital
Principal Investigators:
  • Hai Hu (PRINCIPAL_INVESTIGATOR) - Zhejiang Cancer Hospital
Contact Information
Study Contact:
Ziwen Zhang
+86 13588318799
16660496@qq.com
Ziwen Zhang
+86 13588318799
16660496@qq.com
Zhejiang Cancer Hospital
Interventions
  • Drug: Antitumor treatment plan — This research project included valid data from 600 patients with HER-2 positive advanced or metastatic breast cancer. They were randomly divided into Group A (transition from HP + chemotherapy to HPy + chemotherapy) or Group B (transition from HPy + chemotherapy to HP + chemotherapy) in a 1:1 ratio. Each group had approximately 300 patients. If the patients failed in their first-line treatment, they would switch to another treatment regimen in the second-line treatment. All patients were stopped from treatment when their condition progressed, toxicity became intolerable, or for other reasons. The treatment cycles were recorded.
Study Locations (1 sites)
Zhejiang Cancer Hospital, Zhejiang, Hangzhou 310000 China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily signed the informed consent form with good compliance. 2. Female, aged 18 years or older. 3. Histologically confirmed diagnosis of HER2-positive advanced or metastatic breast cancer. 4. Metastatic lesions confirmed by MRI/contrast-enhanced CT, with at least one measurable lesion according to RECIST 1.1 criteria. 5. For patients previously treated with trastuzumab or tyrosine kinase inhibitors (TKIs) in the early-stage setting, recurrence must have occurred more than 1 year after the completion of prior treatment. 6. ECOG performance status score of 0-2. 7. Eligible patients meeting the treatment criteria specified in this study protocol may be included. This includes:Patients whose prior first-line and second-line treatments both align with the requirements of this protocol;Patients currently receiving second-line treatment whose prior first-line treatment aligns with the requirements of this protocol;The above populations may have previously received or not received trastuzumab and/or pertuzumab, small-molecule tyrosine kinase inhibitors (e.g., pyrotinib, etc.), and may include patients with brain metastases, among others. \- Exclusion Criteria: 1. Known allergy to the drugs involved in this trial or their excipients. 2. Current or recent use of medications that may affect the metabolism or efficacy of pyrotinib or trastuzumab, such as strong CYP3A4 inhibitors (e.g., itraconazole, fluconazole, etc.), strong CYP3A4 inducers (e.g., rifampicin, efavirenz, etc.), or other drugs that may influence the plasma concentration of these two agents. 3. Pregnant or lactating women. 4. Major surgery within 4 weeks prior to the start of study drug administration, with incomplete recovery. Minor procedures such as tumor biopsy, thoracentesis, or venous catheter placement are permitted. 5. Presence of severe systemic diseases and/or uncontrolled infections. 6. Concurrent conditions considered by the investigator to pose a serious risk to patient safety or interfere with the patient's ability to complete the study (e.g., severe hypertension, diabetes, thyroid disorders, concurrent hepatitis B/C, or other active infections). 7. History of other malignancies. 8. Psychiatric illness, cognitive impairment, or inability to comply with the trial protocol and follow-up. 9. Other conditions deemed by the investigator to render the participant unsuitable for inclusion.
Conditions Breast Cancer, Her 2 Positive Breast Can...
Phase Not Applicable
Enrollment 1000
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to describe the real-world utilization patterns of a pertuzumab biosimilar and to evaluate its clinical outcomes in patients with breast cancer in both neoadjuvant and metastatic settings. It also aims to assess pathological complete response (pCR), disease-free survival (DFS) in the neoadjuvant cohort, progression-free survival (PFS) in the metastatic cohort, overall survival (OS), treatment response, and safety and tolerability (adverse events according to CTCAE) across both cohorts.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Primary Outcomes

  • Treatment Regimen Utilization (Up to 36 months)
  • Line of Therapy (Up to 36 months)
  • Treatment Duration (Up to 36 months)
  • Prescribing Context (Up to 36 months)
  • Methods of Response Assessment (Up to 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-15
Completion: 2027-01-15
Eligibility
Age: 19 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Société Algérienne de Formation et Recherche en Oncologie
Collaborators: ES Clinical Research, AlgenPharm
Contact Information
Study Contact:
BOUNEDJAR Adda, Professor
+213 25 20 90 72
contact@esclinicalresearch.com
CAC BLIDA, Algiers, Algeria 16000
Oukkal Mohammed, Professor
+213 219 311 90
contact@esclinicalresearch.com
CHU Béni Messous, Algiers, Algeria 16000
Interventions
N/A
Study Locations (2 sites)
CAC BLIDA, Algiers, Algeria 16000, Algiers, Algeria
CHU Béni Messous, Algiers, Algeria 16000, Algiers, Algeria
Eligibility Criteria
Inclusion Criteria: * Age ≥ 19 years at the time of inclusion; * Histologically confirmed diagnosis of HER2-positive invasive breast cancer (IHC 3+ score or HER2 amplification by FISH/CISH/SISH); * Decision to initiate treatment with a pertuzumab biosimilar in the neoadjuvant setting (neoadjuvant cohort) or as first-line therapy in the metastatic setting (metastatic cohort), in accordance with local indications; * Treatment prescribed as part of routine clinical care (outside of a clinical trial); * Patient informed and having provided written informed consent. Exclusion Criteria: * Treatment with pertuzumab in a therapeutic setting other than neoadjuvant or first-line metastatic (e.g., adjuvant, late recurrence beyond first-line, maintenance therapy alone, etc.); * Treatment administered as part of an interventional clinical trial; * History of severe allergy or known contraindication to pertuzumab; * Medical records unavailable or inability to ensure at least 6 months of minimal follow-up.
Conditions Asthma Exacerbations, Biomarkers / Blood...
Phase NA
Enrollment 240
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to evaluate usual care versus biomarker-directed care (using blood eosinophil counts) for the management of asthma patients in primary care setting. The study hypothesizes that BEC is a valuable biomarker that can guide asthma treatment, and result in reduction in asthma exacerbations, better symptom control and improvement in quality of life compared to usual arm in mild to moderate asthma patients in the primary care setting. Researchers would compare using blood eosinophil count guided to usual care to see if biomarker-directed asthma treatment and management

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Diagnostic Test: Biomarker-directed treatment for asthma management — Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed).
  • Other: Usual Care — Participants in this arm will receive usual asthma care in primary care that does not involve the use of blood eosinophils

Primary Outcomes

  • Time to first asthma exacerbation requiring hospitalisation (Within 12 months from enrollment)
  • Number of asthma exacerbations not requiring hospitalisation (From enrollment to 12 months)
  • Worsening of asthma symptoms (From enrollment to 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-12-03
Completion: 2029-12-31
Eligibility
Age: 21 Years and older
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Healthcare Group Polyclinics
Collaborators: National Medical Research Council (NMRC), Singapore, Singapore General Hospital
Contact Information
Study Contact:
Wern Ee Tang
(65) 6355 3000
wern.ee.tang@nhghealth.com.sg
Wern Ee Tang
(65) 6355 3000
wern.ee.tang@nhghealth.com.sg
National Healthcare Group Polyclinics
Interventions
  • Diagnostic Test: Biomarker-directed treatment for asthma management — Asthma management and treatment for participants in this group will be guided by blood eosinophil count (biomarker-directed).
  • Other: Usual Care — Participants in this arm will receive usual asthma care in primary care that does not involve the use of blood eosinophils
Study Locations (1 sites)
National Healthcare Group Polyclinics, Singapore, 308205 Singapore
Eligibility Criteria
Inclusion Criteria: 1. Singaporeans or Singapore Permanent Residents 2. Patients aged ≥21 to 65 years old 3. Physician diagnosed asthma for duration of at least 4 weeks 4. On or will be initiated on Global Initiative for Asthma (GINA) 2025 step 1-3) treatment 5. No asthma exacerbations\* in the preceding 4 weeks before randomisation 6. Able and willing to attend study appointments approximately every 4-monthly over a 1-year period 7. Able to provide informed consent 8. Stable cardiovascular status (i.e. controlled hypertension, no active symptoms of heart disease or arrhythmias) \*Exacerbations are defined as worsening of asthma symptoms requiring systemic corticosteroid for 3 or more days, emergency department visit, or hospitalization Exclusion Criteria: 1. History of life-threatening asthma requiring intubation or intensive care unit admission 2. Severe asthma or difficult to treat asthma 3. Current use of long-term immunosuppression, LTRA receptor antagonist (Montelukast) and Theophylline or long-term oral steroids 4. Presence of other known causes of eosinophilia besides asthma (e.g. parasitic infection), based on physician's discretion and investigation as per clinical practice and suspicion 5. Current use of beta-blocking agents including eye-drops 6. Use of oral, rectal, or parenteral glucocorticoid within 30 days and/or depot parenteral glucocorticoid within 12 weeks prior to recruitment 7. Known diagnosis of Chronic Obstructive Pulmonary Disease, Interstitial lung disease or bronchiectasis 8. Any significant disease or disorder (eg. Cardiovascular, pulmonary other than asthma, gastrointestinal, hepatic, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or may influence the results of the study, or the patient's ability to participate in the study 9. Current enrolment in other interventional clinical trial for asthma 10. Female subjects who are pregnant or planning pregnancy during the study period 11. Planned travel outside of the country for ≥16 consecutive weeks during the study 12. Investigator's assessment of poor capability of following study instructions or comply with study procedures
Conditions Diabetes Mellitus, Type 2
Phase Not Applicable
Enrollment 400
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Other: No treatment given — No treatment given

Primary Outcomes

  • Cardiometabolic profile: Systolic blood pressure at baseline (At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date)
  • Cardiometabolic profile: Waist circumference at baseline (At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date)
  • Cardiometabolic profile: Hip circumference at baseline (At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date)
  • Cardiometabolic profile: Height at baseline (At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date)
  • Cardiometabolic profile: Weight at baseline (At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date)
  • Cardiometabolic profile: Total cholesterol at baseline (At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date)
  • Cardiometabolic profile: High-density lipoprotein cholesterol (HDL-C) at baseline (At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date)
  • Cardiometabolic profile: Low-density lipoprotein cholesterol (LDL-C) at baseline (At baseline: Measurement at the index date or, if unavailable, the closest measurement within the 12 months prior to the index date)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-13
Completion: 2027-03-27
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: Not specified
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Novo Nordisk A/S
Principal Investigators:
  • Clinical Transparency dept. 2834 (STUDY_DIRECTOR) - Novo Nordisk A/S
Contact Information
Study Contact:
Novo Nordisk
(+1) 866-867-7178
clinicaltrials@novonordisk.com
Interventions
  • Other: No treatment given — No treatment given
Study Locations (6 sites)
Siloam Hospitals Lippo Village, Tangerang, Banten 15810 Indonesia
Siloam Hospitals Surabaya, Surabaya, East Java 60281 Indonesia
University Malaya Medical Centre, Lembah Pantai, Kuala Lumpur 59100 Malaysia
National Heart Institute, Kuala Lumpur, 50400 Malaysia
The Medical City Ortigas, Pasig, National Capital Region 1800 Philippines
Novo Nordisk Investigational Site, Singapore, Singapore
Eligibility Criteria
Inclusion Criteria: * Aged greater than equal to (≥) 40 and less than (\<) 70 years * Male or female * Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023 Exclusion Criteria: * If any exclusion criterion is met, the participant will be excluded from the study. * T1DM or gestational diabetes * Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM * Pregnant women * With pre-existing atherosclerotic CVD including coronary heart disease, stroke, transient ischemic attack, or peripheral artery disease * Died within 12 months after first diagnosis of T2DM * Lost to follow-up i.e., no visit 12 months (± 3 months) after first diagnosis of T2DM